Search company, investor...

Predict your next investment

Private Equity
frazierhealthcare.com

Investments

330

Portfolio Exits

98

Funds

16

Partners & Customers

8

Service Providers

3

About Frazier Healthcare Partners

Frazier Healthcare Partners is a healthcare-focused private equity firm. It was founded in 1991 and is based in Seattle, Washington.

Headquarters Location

Two Union Square 601 Union Street, Suite 3200

Seattle, Washington, 98101,

United States

206-621-7200

Want to inform investors similar to Frazier Healthcare Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing Frazier Healthcare Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Frazier Healthcare Partners in 2 CB Insights research briefs, most recently on May 7, 2020.

Latest Frazier Healthcare Partners News

Frazier Healthcare Partners: Diversity, Equity, Inclusion and ... - PRI

Jan 18, 2023

Free Membership for Qualified Investors and Industry Participants Easily Customize Content to Match Your Investment Preferences Breaking News 24/7/365 Alternative Investment Listings & LeaderBoards Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets,Presentations, Investment Mandates, Video PitchBooks & More! Company Directory AUM Accelerator Program (designed for investment managers) Over 450K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN

Frazier Healthcare Partners Investments

330 Investments

Frazier Healthcare Partners has made 330 investments. Their latest investment was in Alpha-9 Theranostics as part of their Series B on December 12, 2022.

CBI Logo

Frazier Healthcare Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/14/2022

Series B

Alpha-9 Theranostics

$75M

Yes

6

11/14/2022

Series B

MBX Biosciences

$115M

No

10

9/28/2022

Series A

Sudo Biosciences

$37M

Yes

10

1/25/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/30/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/14/2022

11/14/2022

9/28/2022

1/25/2022

11/30/2021

Round

Series B

Series B

Series A

Series B

Series A

Company

Alpha-9 Theranostics

MBX Biosciences

Sudo Biosciences

Subscribe to see more

Subscribe to see more

Amount

$75M

$115M

$37M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

10

10

10

10

Frazier Healthcare Partners Portfolio Exits

98 Portfolio Exits

Frazier Healthcare Partners has 98 portfolio exits. Their latest portfolio exit was OHI on December 22, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/22/2022

Acq - Fin - II

$99M

1

4/29/2022

IPO

$99M

Public

5

12/21/2021

Acquired

$99M

10

11/24/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/16/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/22/2022

4/29/2022

12/21/2021

11/24/2021

7/16/2021

Exit

Acq - Fin - II

IPO

Acquired

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

5

10

10

10

Frazier Healthcare Partners Acquisitions

19 Acquisitions

Frazier Healthcare Partners acquired 19 companies. Their latest acquisition was Apollo Intelligence on June 07, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/7/2022

Debt

$99M

Acq - Fin

2

10/29/2020

Other

$99M

$69.46M

Acq - Fin

2

9/22/2020

$99M

Acq - Fin - III

1

5/5/2020

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

0

1/22/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/7/2022

10/29/2020

9/22/2020

5/5/2020

1/22/2020

Investment Stage

Debt

Other

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$69.46M

$99M

Note

Acq - Fin

Acq - Fin

Acq - Fin - III

Subscribe to see more

Subscribe to see more

Sources

2

2

1

0

10

Frazier Healthcare Partners Fund History

16 Fund Histories

Frazier Healthcare Partners has 16 funds, including Frazier Life Sciences XI.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/16/2022

Frazier Life Sciences XI

$987M

1

10/28/2021

Frazier Life Sciences Public Fund

$830M

1

5/27/2021

Frazier Healthcare Growth Buyout Fund X

$1,400M

1

1/16/2020

Frazier Life Sciences X

Subscribe to see more

Subscribe to see more

$99M

10

4/10/2018

Frazier Healthcare Growth Buyout Fund XI

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/16/2022

10/28/2021

5/27/2021

1/16/2020

4/10/2018

Fund

Frazier Life Sciences XI

Frazier Life Sciences Public Fund

Frazier Healthcare Growth Buyout Fund X

Frazier Life Sciences X

Frazier Healthcare Growth Buyout Fund XI

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$987M

$830M

$1,400M

$99M

$99M

Sources

1

1

1

10

10

Frazier Healthcare Partners Partners & Customers

8 Partners and customers

Frazier Healthcare Partners has 8 strategic partners and customers. Frazier Healthcare Partners recently partnered with Pivotal bioVenture Partners China on December 12, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

12/3/2021

Partner

China

News - Pivotal bioVenture Partners China Announces Formation of SanReno Therapeutics

SanReno Therapeutics is a joint venture with an investor syndicate led by Pivotal bioVenture Partners China and Frazier Healthcare Partners to develop , manufacture and commercialize kidney disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan , as well as Singapore , and Chinook Therapeutics , Inc. has granted SanReno Therapeutics exclusive rights to develop and commercialize atrasentan and BION-1301 in Greater China and Singapore .

1

7/30/2021

Licensor

Japan

Subscribe to see more

Subscribe to see more

10

5/16/2019

Partner

Japan

Subscribe to see more

Subscribe to see more

10

2/6/2019

Partner

United States

Subscribe to see more

Subscribe to see more

10

12/17/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

12/3/2021

7/30/2021

5/16/2019

2/6/2019

12/17/2018

Type

Partner

Licensor

Partner

Partner

Partner

Business Partner

Country

China

Japan

Japan

United States

United States

News Snippet

News - Pivotal bioVenture Partners China Announces Formation of SanReno Therapeutics

SanReno Therapeutics is a joint venture with an investor syndicate led by Pivotal bioVenture Partners China and Frazier Healthcare Partners to develop , manufacture and commercialize kidney disease therapies in Greater China , which includes mainland China , Hong Kong , Macau and Taiwan , as well as Singapore , and Chinook Therapeutics , Inc. has granted SanReno Therapeutics exclusive rights to develop and commercialize atrasentan and BION-1301 in Greater China and Singapore .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Frazier Healthcare Partners Service Providers

3 Service Providers

Frazier Healthcare Partners has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - Fin - II

Investment Bank

Financial Advisor, Sole Bookrunner, Sole Lead Arranger

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - Fin - II

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor, Sole Bookrunner, Sole Lead Arranger

Subscribe to see more

Partnership data by VentureSource

Frazier Healthcare Partners Team

22 Team Members

Frazier Healthcare Partners has 22 team members, including current President, Kelly McCullum.

Name

Work History

Title

Status

Kelly McCullum

President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Kelly McCullum

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.